Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of Oncology

Volumn 29, Issue 4, 2018, Pages 959-965

  Vokes, Everett E ^a   Ready, N ^b   Felip, E ^c   Horn, L ^d   Burgio, M A ^e   Antonia, S J ^f   Frontera, O Arén ^g   Gettinger, S ^h   Holgado, E ⁱ   Spigel, D ^j,k   Waterhouse, D ^l,m   Domine, M ⁿ   Garassino, M ^o   Chow, L Q M ^p   Blumenschein, G ^q   Barlesi, F ^r   Coudert, B ^s   Gainor, J ^t   Arrieta, O ^u   Brahmer, J ^v   Butts, C ^w   Steins, M ^x   Geese, W J ^y   Li, A ^y   Healey, D ^y   Crino L ^e   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Centro Internacional de Estudios Clinicos   (Chile)

^h YALE CANCER CENTER   (United States)

ⁱ Hospital de Madrid   (Spain)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k Enkema amp   (United States)

^l OHC ^*  (United States)

^m US Oncology   (United States)

ⁿ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p UNIVERSITY OF WASHINGTON   (United States)

^q UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^r AIX MARSEILLE UNIVERSITY   (France)

^s CENTRE GEORGES FRANÇOIS LECLERC   (France)

^t MASSACHUSETTS GENERAL HOSPITAL   (United States)

^u INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^v JOHNS HOPKINS UNIVERSITY   (United States)

^w CROSS CANCER INSTITUTE   (Canada)

^x UNIVERSITY OF HEIDELBERG   (Germany)

^y BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Liver metastases; Nivolumab; NSCLC

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; NIVOLUMAB; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ADVERSE EVENT; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; AGED; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOCETAXEL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIVOLUMAB; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85046647216     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy041     Document Type: Article

References (21)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108
2. American Cancer Society. Lung cancer (non-small cell). American Cancer Society website. http://www.cancer.org/cancer/lungcancer-nonsmallcell/ detailedguide/non-small-cell-lung-cancer-what-is-non-smallcell-lung-cancer (8 June 2016, date last accessed)
3. OPDIVOVR (Nivolumab) [Package Insert]. Princeton, NJ, Bristol-Myers Squibb Company 2018
4. OPDIVOVR (Nivolumab) [Summary of Product Characteristics]. Uxbridge, UK, Bristol-Myers Squibb Company 2018
5. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627-1639
6. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123-135
7. Horn L, Spigel DR, Vokes EE et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: twoyear outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35(35): 3924-3933
8. Kagohashi K, Satoh H, Ishikawa H et al. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol 2003; 20(1): 25-28
9. Tamura T, Kurishima K, Nakazawa K et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 2015; 3(1): 217-221
10. Riihimaki M, Hemminki A, Fallah M et al. Metastatic sites and survival in lung cancer. Lung Cancer 2014; 86(1): 78-84
11. Görg C, Schwerk WB, Wolf M, Havemann K. Prognostic value of response to chemotherapy using ultrasound in lung cancer with metastatic liver involvement. Bildgebung 1990; 57: 70-73
12. Yamamoto N, Tamura T, Fukuoka M, Saijo N. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 1999; 15: 737-741
13. Bearz A, Garassino I, Tiseo M et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010; 68(2): 264-268
14. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30(4): 419-425
15. Soto-Parra H, Defraia E, Pozzessere D et al. Analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab: the Italian Expanded Access Program experience [abstract P9237]. Presented at the World Conference on Lung Cancer Congress; October 15-18, 2017; Yokohama, Japan
16. Goldman JW, Crino L, Vokes EE et al. Nivolumab in patients with advanced NSCLC and central nervous system metastases [abstract P9038]. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, USA
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247
18. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4(5): 702-709
19. Hoang T, Xu R, Schiller JH et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005; 23(1): 175-183
20. Ren Y, Dai C, Zheng H et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget 2016; 7(33): 53245-53253
21. Tumeh PC, Hellmann MD, Hamid O et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 2017; 5(5): 417-424